Moreover, panobinostat was shown to synergize with PD-L1 blockades by different mechanisms such as promotion of NK cell–target cell conjugation formation by increasing the expression of cell adhesion- and tight junction-related genes and by increasing the expression of CD80, CD86 (ligands for CD28), and CD112 (PVRL2/nectin-2 ligand for activating the DNAM-1 NK cell receptor) on tumor cells [211]. The gene discussed is NECTIN2; the disease is neoplasm.